Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Hamid Mobedi

Hamid Mobedi

Iran Polymer and Petrochemical Institute, Iran

Title: In situ-forming drug delivery system for treatment of chronic osteomyelitis

Biography

Biography: Hamid Mobedi

Abstract

Bacterial bone infection, or osteomyelitis, poses a considerable problem for successful orthopedic involvement, that frequently leads to bone loss and the spread of infection to the surrounding tissues. Local delivery of high doses of antibiotics, minimizing potential systemic toxicity, is popular in treating osteomyelitis because it can facilitate the delivery of antibiotics by diffusion into avascular areas that are not accessible by systemic antibiotics therapy. The most widely applied material is polymethylmethacrylate (PMMA) beads loaded with antibiotic, which was proven to be successful in the treatment and prevention of osseous infections. An alternative approach is to use a biodegradable polymer, that is eliminating the need for a secondary surgical procedure to remove the foreign object. In addition, due to its degradation in the implantation area, the drug carrier does not prevent the formation of new bones. Nowadays, the controlled drug delivery systems that are based on polymeric solution have received considerable attention. In these systems, known as in situ-forming implants, drug release is controlled by the asymmetric membrane that are formed by polymer phase inversion. In this study effect of some factores like solvent water affinity and drug hydrophilicity on the release profile was investigated and prepared formulations were evaluated by drug release, morphology, injectibility and bactericidal assay. Finally, we prepared an in situ-forming implant with controlled amount of drug release in the first day and sustained release over 6 weeks. The concentration of antibiotic remained well above the minimum bactericidal concentration (MBC) in the theraputic period.